Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Retension Pharmaceuticals (Nasdaq: RTSN) management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retension Pharmaceuticals (Nasdaq: RTSN) management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.
The chat is scheduled for 7:30 a.m. ET. The conference runs November 9–11 in Boston, Massachusetts. A live webcast will be available through the News & Events page in the company's Investor Relations section.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9–11, 2026, in Boston, Massachusetts.
Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Fireside chat
Date: Tuesday, November 10, 2026
Time: 7:30 a.m. ET
A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investor Relations section of the Retension Pharmaceuticals website.
About Retension Pharmaceuticals
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.
About RTN-001
Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 enrolled subjects. In two Phase 2 pilot trials, RTN-001 has achieved clinically meaningful placebo-adjusted reductions in systolic blood pressure and diastolic blood pressure in patients with hypertension. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A.
Contact:
Press and Investor Contact
Alex Schwartz
Chief Financial Officer
investors@retensionpharmaceuticals.com
